Gene therapy for inherited retinal degeneration from RDH12
Part of Eyes & vision clinical trials.
This trial tests a one-time gene therapy given under the retina to treat a rare inherited eye disease that causes poor vision. It may help slow down vision loss or improve sight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older (adults and adolescents).
- You have a confirmed RDH12 gene change and a diagnosis of Leber congenital amaurosis (a type of inherited retinal degeneration).
- Your vision is reduced to 20/40 or worse in at least one eye.
- You have not had gene therapy before and are in generally good health for eye surgery.
- You have not had eye surgery within the last 90 days and do not have an active eye infection or inflammation.
- You can attend all study visits and follow the doctors' instructions after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy called ATSN-201 for people with X-linked retinoschisis (XLRS), a condition that affects the retina and can cause vision loss. The therapy aims to fix the faulty gene that causes the condition, potentially halting vision loss and improving vision. Participants receive a one-time injection into the eye, and the study monitors safety and effectiveness.
This trial tests an injection called PUMCH-E101 for people with vision loss caused by changes in the RDH12 gene. The goal is to see if it is safe and if it can help improve vision.
This trial tests a gene therapy injection into the eye to improve vision in people with a specific type of inherited optic nerve disease called Leber’s hereditary optic neuropathy (LHON). It is aimed at people who have a particular genetic change and a history of vision loss lasting long enough to measure change, while checking for safety first.
This trial tests two doses of a gene therapy (AGTC-501) in males who already had one eye treated with a similar gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. The goal is to see if the treatment is safe and can help preserve or improve vision.
This trial tests a gene therapy called GS010 given as an injection into the eye for people with vision loss from LHON. It aims to see if it can help improve vision in both eyes.
This trial tests an experimental gene therapy for people with a specific type of retinitis pigmentosa caused by a change in the RHO gene. The therapy is given in multiple doses to see if it is safe and helpful.
Hear when a new Leber Congenital Amaurosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.